CytRx, Connaught Laboratories Inc. deal

CYTR's Vaxcel Inc. subsidiary and Connaught signed an option agreement under which Connaught (Swiftwater, Penn.) can exclusively evaluate Vaxcel's Optivax System in combination with a Connaught vaccine under development to prevent an infectious disease.

Optivax combines a purified antigen with a copolymer. The purified antigen enables the delivery of a higher concentration of the vaccine, while the copolymer makes the molecule large enough for the body to recognize it. The goal of the system is to create single-dose formulations for vaccines that require multiple injections and create oral vaccines for injectable products, CYTR said. ...